Share Price and Basic Stock Data
Last Updated: December 29, 2025, 12:35 pm
| PEG Ratio | 3.74 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Aurobindo Pharma Ltd, a prominent player in the Indian pharmaceuticals sector, reported a stock price of ₹1,206 and a market capitalization of ₹70,056 Cr. The company has demonstrated substantial revenue growth, with sales rising from ₹24,775 Cr in FY 2021 to ₹31,724 Cr in FY 2025, reflecting a compound annual growth rate (CAGR) of approximately 6.5%. Quarterly sales have shown a consistent upward trajectory, with ₹7,219 Cr reported in September 2023 and projected to reach ₹8,382 Cr by March 2025. This upward trend in sales is indicative of increasing demand for its generic and specialty pharmaceuticals, supported by a robust product pipeline. The company’s operating profit margin (OPM) also improved significantly, standing at 20% in FY 2025 compared to 15% in FY 2023, showcasing enhanced operational efficiency. Aurobindo’s ability to navigate the complexities of the pharmaceutical market while expanding its revenue base positions it favorably against industry competitors.
Profitability and Efficiency Metrics
Aurobindo Pharma’s profitability metrics reveal a solid financial performance, with net profit rising from ₹1,928 Cr in FY 2023 to ₹3,484 Cr in FY 2025, equating to an impressive net profit margin of 11.08%. The company’s return on equity (ROE) stood at 11.1%, while the return on capital employed (ROCE) was reported at 14.2%. These figures indicate effective capital utilization and a strong return on shareholder investments. The interest coverage ratio (ICR) of 15.76x demonstrates the company’s strong ability to meet interest obligations, reflecting financial stability. However, the cash conversion cycle (CCC) at 244 days suggests potential inefficiencies in managing working capital, particularly in inventory and receivables management. The operating profit margin (OPM) increased to 20%, suggesting improved cost management and operational efficiency. Overall, Aurobindo’s profitability metrics position it as a competitive player in the pharmaceutical industry.
Balance Sheet Strength and Financial Ratios
Aurobindo Pharma’s balance sheet reflects a robust financial structure, with total assets amounting to ₹49,482 Cr and total liabilities reported at ₹49,482 Cr as of March 2025. The company’s reserves increased to ₹34,983 Cr, indicating a strong equity base. Borrowings stood at ₹7,794 Cr, translating to a total debt-to-equity ratio of 0.24, which is relatively low and signals prudent financial management. The current ratio of 1.85 and quick ratio of 1.13 indicate good liquidity, allowing the company to meet short-term obligations comfortably. The price-to-book value ratio (P/BV) was reported at 2.06x, which, while higher than the sector average, reflects investor confidence in Aurobindo’s growth prospects. Moreover, the enterprise value (EV) of ₹67,055 Cr suggests a strong market position. Overall, Aurobindo’s financial ratios and balance sheet strength underline its capability to sustain growth and navigate market challenges.
Shareholding Pattern and Investor Confidence
Aurobindo Pharma’s shareholding pattern indicates a stable ownership structure, with promoters holding 51.82% of the total shares. Foreign institutional investors (FIIs) have decreased their stake from 22.31% in December 2022 to 14.21% by September 2025, suggesting a cautious approach amid market volatility. Conversely, domestic institutional investors (DIIs) increased their holdings from 14.90% to 27.60% during the same period, reflecting growing confidence among local investors. The public shareholding segment has seen a decline, from 10.96% in December 2022 to 6.37% in September 2025, which could indicate a consolidation of ownership among institutional players. With a total of 2,47,662 shareholders, Aurobindo appears to maintain a diverse investor base, which is critical for long-term stability. This evolving shareholding pattern highlights shifting confidence levels among different investor groups, which could impact the stock’s performance in the future.
Outlook, Risks, and Final Insight
Aurobindo Pharma’s outlook remains positive, driven by strong revenue growth and improving profitability metrics. However, the company faces risks including potential regulatory challenges and pricing pressures in the generic drug market, which could impact margins. The declining trend in foreign institutional investment raises concerns about external perceptions of the company’s growth trajectory. Additionally, the high cash conversion cycle indicates that improving operational efficiencies will be crucial for sustaining profitability. Should Aurobindo successfully address these risks while leveraging its strong market position and product pipeline, it could enhance its competitive advantage and shareholder value. Conversely, failure to manage these challenges could hinder growth prospects. Thus, investor sentiment will be key in determining Aurobindo’s future performance in the dynamic pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 99.8 | 231/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,830 Cr. | 443 | 479/192 | 100 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.3 Cr. | 49.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 50.6 Cr. | 34.6 | 35.0/17.0 | 120 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,069.00 Cr | 1,146.23 | 52.39 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5,739 | 6,407 | 6,473 | 6,851 | 7,219 | 7,352 | 7,580 | 7,567 | 7,796 | 7,979 | 8,382 | 7,868 | 8,286 |
| Expenses | 4,950 | 5,453 | 5,477 | 5,702 | 5,846 | 5,753 | 5,920 | 5,949 | 6,230 | 6,401 | 6,622 | 6,265 | 6,608 |
| Operating Profit | 790 | 954 | 996 | 1,149 | 1,373 | 1,599 | 1,660 | 1,618 | 1,566 | 1,578 | 1,760 | 1,603 | 1,678 |
| OPM % | 14% | 15% | 15% | 17% | 19% | 22% | 22% | 21% | 20% | 20% | 21% | 20% | 20% |
| Other Income | 57 | 93 | 135 | 47 | 188 | 163 | 14 | 221 | 136 | 159 | 135 | 107 | 122 |
| Interest | 25 | 45 | 56 | 57 | 68 | 76 | 89 | 111 | 113 | 118 | 115 | 98 | 95 |
| Depreciation | 298 | 321 | 346 | 327 | 418 | 423 | 354 | 404 | 382 | 419 | 444 | 406 | 429 |
| Profit before tax | 523 | 680 | 730 | 812 | 1,076 | 1,262 | 1,230 | 1,324 | 1,207 | 1,200 | 1,335 | 1,207 | 1,276 |
| Tax % | 22% | 28% | 31% | 30% | 30% | 26% | 26% | 31% | 32% | 30% | 32% | 32% | 34% |
| Net Profit | 410 | 491 | 506 | 570 | 752 | 940 | 907 | 918 | 817 | 846 | 903 | 824 | 848 |
| EPS in Rs | 6.99 | 8.38 | 8.64 | 9.74 | 12.92 | 15.98 | 15.51 | 15.69 | 14.07 | 14.56 | 15.56 | 14.20 | 14.61 |
Last Updated: December 27, 2025, 11:46 pm
Below is a detailed analysis of the quarterly data for Aurobindo Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 8,286.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,868.00 Cr. (Jun 2025) to 8,286.00 Cr., marking an increase of 418.00 Cr..
- For Expenses, as of Sep 2025, the value is 6,608.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,265.00 Cr. (Jun 2025) to 6,608.00 Cr., marking an increase of 343.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 1,678.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,603.00 Cr. (Jun 2025) to 1,678.00 Cr., marking an increase of 75.00 Cr..
- For OPM %, as of Sep 2025, the value is 20.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 20.00%.
- For Other Income, as of Sep 2025, the value is 122.00 Cr.. The value appears strong and on an upward trend. It has increased from 107.00 Cr. (Jun 2025) to 122.00 Cr., marking an increase of 15.00 Cr..
- For Interest, as of Sep 2025, the value is 95.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 98.00 Cr. (Jun 2025) to 95.00 Cr., marking a decrease of 3.00 Cr..
- For Depreciation, as of Sep 2025, the value is 429.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 406.00 Cr. (Jun 2025) to 429.00 Cr., marking an increase of 23.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 1,276.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,207.00 Cr. (Jun 2025) to 1,276.00 Cr., marking an increase of 69.00 Cr..
- For Tax %, as of Sep 2025, the value is 34.00%. The value appears to be increasing, which may not be favorable. It has increased from 32.00% (Jun 2025) to 34.00%, marking an increase of 2.00%.
- For Net Profit, as of Sep 2025, the value is 848.00 Cr.. The value appears strong and on an upward trend. It has increased from 824.00 Cr. (Jun 2025) to 848.00 Cr., marking an increase of 24.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 14.61. The value appears strong and on an upward trend. It has increased from 14.20 (Jun 2025) to 14.61, marking an increase of 0.41.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:09 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8,089 | 12,103 | 13,772 | 14,910 | 16,463 | 19,564 | 23,099 | 24,775 | 23,455 | 24,855 | 29,002 | 31,724 | 32,514 |
| Expenses | 5,951 | 9,524 | 10,579 | 11,469 | 12,691 | 15,612 | 18,249 | 19,497 | 19,060 | 21,148 | 23,176 | 25,173 | 25,896 |
| Operating Profit | 2,137 | 2,579 | 3,193 | 3,441 | 3,772 | 3,952 | 4,849 | 5,278 | 4,396 | 3,707 | 5,826 | 6,551 | 6,619 |
| OPM % | 26% | 21% | 23% | 23% | 23% | 20% | 21% | 21% | 19% | 15% | 20% | 21% | 20% |
| Other Income | 18 | 81 | 200 | 115 | 105 | 70 | 166 | 3,195 | 152 | 291 | 366 | 622 | 523 |
| Interest | 310 | 160 | 257 | 67 | 78 | 263 | 305 | 74 | 49 | 140 | 290 | 457 | 426 |
| Depreciation | 313 | 333 | 392 | 428 | 558 | 668 | 967 | 1,055 | 1,127 | 1,245 | 1,522 | 1,649 | 1,698 |
| Profit before tax | 1,533 | 2,168 | 2,744 | 3,061 | 3,241 | 3,091 | 3,743 | 7,344 | 3,373 | 2,612 | 4,380 | 5,066 | 5,018 |
| Tax % | 24% | 28% | 26% | 25% | 25% | 24% | 24% | 27% | 22% | 26% | 28% | 31% | |
| Net Profit | 1,169 | 1,571 | 2,024 | 2,301 | 2,423 | 2,364 | 2,844 | 5,334 | 2,647 | 1,928 | 3,169 | 3,484 | 3,421 |
| EPS in Rs | 20.12 | 26.98 | 34.61 | 39.29 | 41.36 | 40.36 | 48.56 | 91.05 | 45.20 | 32.90 | 54.15 | 60.02 | 58.93 |
| Dividend Payout % | 7% | 8% | 7% | 6% | 6% | 6% | 6% | 4% | 20% | 23% | 8% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 34.39% | 28.84% | 13.69% | 5.30% | -2.43% | 20.30% | 87.55% | -50.37% | -27.16% | 64.37% | 9.94% |
| Change in YoY Net Profit Growth (%) | 0.00% | -5.55% | -15.15% | -8.38% | -7.74% | 22.74% | 67.25% | -137.93% | 23.21% | 91.53% | -54.43% |
Aurobindo Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 7% |
| 3 Years: | 11% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 4% |
| 3 Years: | 8% |
| TTM: | -5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 5% |
| 3 Years: | 24% |
| 1 Year: | -32% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 12% |
| 3 Years: | 10% |
| Last Year: | 11% |
Last Updated: September 5, 2025, 2:31 pm
Balance Sheet
Last Updated: December 10, 2025, 3:52 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 29 | 29 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 58 | 58 |
| Reserves | 3,721 | 5,127 | 7,229 | 9,313 | 11,622 | 13,832 | 16,766 | 21,871 | 24,517 | 26,781 | 29,784 | 32,595 | 34,983 |
| Borrowings | 3,769 | 4,451 | 5,041 | 3,364 | 4,770 | 6,967 | 5,826 | 5,339 | 2,851 | 5,286 | 6,648 | 8,263 | 7,794 |
| Other Liabilities | 1,970 | 3,303 | 3,568 | 3,464 | 4,492 | 5,414 | 6,113 | 6,147 | 6,211 | 7,379 | 8,227 | 8,566 | 9,710 |
| Total Liabilities | 9,490 | 12,910 | 15,896 | 16,200 | 20,942 | 26,271 | 28,765 | 33,416 | 33,638 | 39,505 | 44,717 | 49,482 | 52,546 |
| Fixed Assets | 2,722 | 3,706 | 4,180 | 4,834 | 6,521 | 8,475 | 9,396 | 9,374 | 10,532 | 11,024 | 14,493 | 14,794 | 17,741 |
| CWIP | 310 | 420 | 848 | 1,458 | 1,583 | 1,668 | 1,986 | 3,062 | 3,747 | 5,390 | 3,869 | 4,900 | 3,039 |
| Investments | 20 | 20 | 123 | 246 | 312 | 360 | 555 | 591 | 997 | 543 | 372 | 252 | 268 |
| Other Assets | 6,439 | 8,765 | 10,745 | 9,662 | 12,527 | 15,768 | 16,827 | 20,390 | 18,362 | 22,549 | 25,983 | 29,536 | 31,498 |
| Total Assets | 9,490 | 12,910 | 15,896 | 16,200 | 20,942 | 26,271 | 28,765 | 33,416 | 33,638 | 39,505 | 44,717 | 49,482 | 52,546 |
Below is a detailed analysis of the balance sheet data for Aurobindo Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 58.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 58.00 Cr..
- For Reserves, as of Sep 2025, the value is 34,983.00 Cr.. The value appears strong and on an upward trend. It has increased from 32,595.00 Cr. (Mar 2025) to 34,983.00 Cr., marking an increase of 2,388.00 Cr..
- For Borrowings, as of Sep 2025, the value is 7,794.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 8,263.00 Cr. (Mar 2025) to 7,794.00 Cr., marking a decrease of 469.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 9,710.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8,566.00 Cr. (Mar 2025) to 9,710.00 Cr., marking an increase of 1,144.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 52,546.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 49,482.00 Cr. (Mar 2025) to 52,546.00 Cr., marking an increase of 3,064.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 17,741.00 Cr.. The value appears strong and on an upward trend. It has increased from 14,794.00 Cr. (Mar 2025) to 17,741.00 Cr., marking an increase of 2,947.00 Cr..
- For CWIP, as of Sep 2025, the value is 3,039.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,900.00 Cr. (Mar 2025) to 3,039.00 Cr., marking a decrease of 1,861.00 Cr..
- For Investments, as of Sep 2025, the value is 268.00 Cr.. The value appears strong and on an upward trend. It has increased from 252.00 Cr. (Mar 2025) to 268.00 Cr., marking an increase of 16.00 Cr..
- For Other Assets, as of Sep 2025, the value is 31,498.00 Cr.. The value appears strong and on an upward trend. It has increased from 29,536.00 Cr. (Mar 2025) to 31,498.00 Cr., marking an increase of 1,962.00 Cr..
- For Total Assets, as of Sep 2025, the value is 52,546.00 Cr.. The value appears strong and on an upward trend. It has increased from 49,482.00 Cr. (Mar 2025) to 52,546.00 Cr., marking an increase of 3,064.00 Cr..
Notably, the Reserves (34,983.00 Cr.) exceed the Borrowings (7,794.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.00 | -2.00 | -2.00 | 0.00 | -1.00 | -3.00 | -1.00 | 0.00 | 2.00 | -2.00 | -1.00 | -2.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 119 | 107 | 122 | 68 | 68 | 64 | 68 | 52 | 62 | 66 | 61 | 66 |
| Inventory Days | 240 | 239 | 240 | 246 | 317 | 304 | 289 | 333 | 272 | 275 | 284 | 295 |
| Days Payable | 137 | 136 | 146 | 122 | 128 | 107 | 97 | 103 | 97 | 125 | 129 | 117 |
| Cash Conversion Cycle | 222 | 210 | 217 | 191 | 257 | 260 | 260 | 282 | 237 | 216 | 216 | 244 |
| Working Capital Days | 56 | 50 | 44 | 51 | 50 | 25 | 35 | 52 | 84 | 55 | 66 | 49 |
| ROCE % | 27% | 27% | 27% | 25% | 23% | 18% | 19% | 18% | 13% | 9% | 14% | 14% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid Cap Fund | 13,344,745 | 1.78 | 1637 | N/A | N/A | N/A |
| SBI Large & Midcap Fund | 6,500,000 | 2.15 | 797.36 | N/A | N/A | N/A |
| Quant Mid Cap Fund | 5,969,000 | 8.77 | 732.22 | N/A | N/A | N/A |
| Quant ELSS Tax Saver Fund | 5,174,277 | 5.07 | 634.73 | 4,218,986 | 2025-11-02 15:07:43 | 22.64% |
| ICICI Prudential India Opportunities Fund | 4,700,125 | 1.7 | 576.56 | 5,261,125 | 2025-12-15 07:18:56 | -10.66% |
| Quant Multi Cap Fund | 4,294,483 | 5.98 | 526.8 | N/A | N/A | N/A |
| ICICI Prudential Value Fund | 3,230,588 | 0.66 | 396.3 | N/A | N/A | N/A |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 3,180,505 | 6.04 | 390.15 | 4,305,998 | 2025-12-15 07:18:56 | -26.14% |
| Quant Flexi Cap Fund | 3,030,611 | 5.41 | 371.77 | N/A | N/A | N/A |
| HDFC Balanced Advantage Fund | 2,722,312 | 0.31 | 333.95 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 59.81 | 54.16 | 32.90 | 45.19 | 91.05 |
| Diluted EPS (Rs.) | 59.81 | 54.16 | 32.90 | 45.19 | 91.05 |
| Cash EPS (Rs.) | 88.92 | 80.35 | 54.34 | 64.94 | 109.99 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 562.21 | 509.49 | 458.30 | 419.42 | 374.28 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 562.21 | 509.49 | 458.30 | 419.42 | 374.28 |
| Revenue From Operations / Share (Rs.) | 546.21 | 495.00 | 424.23 | 400.33 | 422.85 |
| PBDIT / Share (Rs.) | 124.05 | 109.24 | 68.43 | 80.34 | 97.53 |
| PBIT / Share (Rs.) | 95.65 | 83.27 | 47.19 | 61.11 | 79.52 |
| PBT / Share (Rs.) | 87.78 | 75.05 | 44.79 | 58.10 | 126.28 |
| Net Profit / Share (Rs.) | 60.52 | 54.38 | 33.10 | 45.71 | 91.98 |
| NP After MI And SOA / Share (Rs.) | 60.02 | 54.16 | 32.90 | 45.20 | 91.05 |
| PBDIT Margin (%) | 22.71 | 22.06 | 16.13 | 20.06 | 23.06 |
| PBIT Margin (%) | 17.51 | 16.82 | 11.12 | 15.26 | 18.80 |
| PBT Margin (%) | 16.06 | 15.16 | 10.55 | 14.51 | 29.86 |
| Net Profit Margin (%) | 11.08 | 10.98 | 7.80 | 11.41 | 21.75 |
| NP After MI And SOA Margin (%) | 10.98 | 10.94 | 7.75 | 11.29 | 21.53 |
| Return on Networth / Equity (%) | 10.67 | 10.63 | 7.18 | 10.77 | 24.32 |
| Return on Capital Employeed (%) | 15.82 | 14.84 | 9.73 | 13.89 | 20.09 |
| Return On Assets (%) | 7.00 | 7.03 | 4.83 | 7.80 | 15.75 |
| Long Term Debt / Equity (X) | 0.04 | 0.07 | 0.02 | 0.01 | 0.01 |
| Total Debt / Equity (X) | 0.24 | 0.21 | 0.18 | 0.09 | 0.22 |
| Asset Turnover Ratio (%) | 0.66 | 0.68 | 0.67 | 0.69 | 0.78 |
| Current Ratio (X) | 1.85 | 1.98 | 1.87 | 2.22 | 1.86 |
| Quick Ratio (X) | 1.13 | 1.18 | 1.13 | 1.30 | 1.01 |
| Inventory Turnover Ratio (X) | 3.12 | 1.18 | 1.20 | 0.88 | 0.99 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 22.79 | 9.95 | 4.39 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 13.85 | 6.98 | 3.66 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 77.21 | 90.05 | 95.61 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 86.15 | 93.02 | 96.34 |
| Interest Coverage Ratio (X) | 15.76 | 22.09 | 28.54 | 96.77 | 76.71 |
| Interest Coverage Ratio (Post Tax) (X) | 8.69 | 12.66 | 14.80 | 58.70 | 35.56 |
| Enterprise Value (Cr.) | 67055.18 | 63875.80 | 29138.94 | 37374.61 | 51145.96 |
| EV / Net Operating Revenue (X) | 2.11 | 2.20 | 1.17 | 1.59 | 2.06 |
| EV / EBITDA (X) | 9.31 | 9.98 | 7.27 | 7.94 | 8.95 |
| MarketCap / Net Operating Revenue (X) | 2.12 | 2.20 | 1.22 | 1.67 | 2.08 |
| Retention Ratios (%) | 0.00 | 0.00 | 77.20 | 90.04 | 95.60 |
| Price / BV (X) | 2.06 | 2.14 | 1.13 | 1.59 | 2.36 |
| Price / Net Operating Revenue (X) | 2.12 | 2.20 | 1.22 | 1.67 | 2.08 |
| EarningsYield | 0.05 | 0.04 | 0.06 | 0.06 | 0.10 |
After reviewing the key financial ratios for Aurobindo Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 59.81. This value is within the healthy range. It has increased from 54.16 (Mar 24) to 59.81, marking an increase of 5.65.
- For Diluted EPS (Rs.), as of Mar 25, the value is 59.81. This value is within the healthy range. It has increased from 54.16 (Mar 24) to 59.81, marking an increase of 5.65.
- For Cash EPS (Rs.), as of Mar 25, the value is 88.92. This value is within the healthy range. It has increased from 80.35 (Mar 24) to 88.92, marking an increase of 8.57.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 562.21. It has increased from 509.49 (Mar 24) to 562.21, marking an increase of 52.72.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 562.21. It has increased from 509.49 (Mar 24) to 562.21, marking an increase of 52.72.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 546.21. It has increased from 495.00 (Mar 24) to 546.21, marking an increase of 51.21.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 124.05. This value is within the healthy range. It has increased from 109.24 (Mar 24) to 124.05, marking an increase of 14.81.
- For PBIT / Share (Rs.), as of Mar 25, the value is 95.65. This value is within the healthy range. It has increased from 83.27 (Mar 24) to 95.65, marking an increase of 12.38.
- For PBT / Share (Rs.), as of Mar 25, the value is 87.78. This value is within the healthy range. It has increased from 75.05 (Mar 24) to 87.78, marking an increase of 12.73.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 60.52. This value is within the healthy range. It has increased from 54.38 (Mar 24) to 60.52, marking an increase of 6.14.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 60.02. This value is within the healthy range. It has increased from 54.16 (Mar 24) to 60.02, marking an increase of 5.86.
- For PBDIT Margin (%), as of Mar 25, the value is 22.71. This value is within the healthy range. It has increased from 22.06 (Mar 24) to 22.71, marking an increase of 0.65.
- For PBIT Margin (%), as of Mar 25, the value is 17.51. This value is within the healthy range. It has increased from 16.82 (Mar 24) to 17.51, marking an increase of 0.69.
- For PBT Margin (%), as of Mar 25, the value is 16.06. This value is within the healthy range. It has increased from 15.16 (Mar 24) to 16.06, marking an increase of 0.90.
- For Net Profit Margin (%), as of Mar 25, the value is 11.08. This value exceeds the healthy maximum of 10. It has increased from 10.98 (Mar 24) to 11.08, marking an increase of 0.10.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.98. This value is within the healthy range. It has increased from 10.94 (Mar 24) to 10.98, marking an increase of 0.04.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.67. This value is below the healthy minimum of 15. It has increased from 10.63 (Mar 24) to 10.67, marking an increase of 0.04.
- For Return on Capital Employeed (%), as of Mar 25, the value is 15.82. This value is within the healthy range. It has increased from 14.84 (Mar 24) to 15.82, marking an increase of 0.98.
- For Return On Assets (%), as of Mar 25, the value is 7.00. This value is within the healthy range. It has decreased from 7.03 (Mar 24) to 7.00, marking a decrease of 0.03.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.07 (Mar 24) to 0.04, marking a decrease of 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has increased from 0.21 (Mar 24) to 0.24, marking an increase of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.66. It has decreased from 0.68 (Mar 24) to 0.66, marking a decrease of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.85. This value is within the healthy range. It has decreased from 1.98 (Mar 24) to 1.85, marking a decrease of 0.13.
- For Quick Ratio (X), as of Mar 25, the value is 1.13. This value is within the healthy range. It has decreased from 1.18 (Mar 24) to 1.13, marking a decrease of 0.05.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.12. This value is below the healthy minimum of 4. It has increased from 1.18 (Mar 24) to 3.12, marking an increase of 1.94.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 15.76. This value is within the healthy range. It has decreased from 22.09 (Mar 24) to 15.76, marking a decrease of 6.33.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.69. This value is within the healthy range. It has decreased from 12.66 (Mar 24) to 8.69, marking a decrease of 3.97.
- For Enterprise Value (Cr.), as of Mar 25, the value is 67,055.18. It has increased from 63,875.80 (Mar 24) to 67,055.18, marking an increase of 3,179.38.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has decreased from 2.20 (Mar 24) to 2.11, marking a decrease of 0.09.
- For EV / EBITDA (X), as of Mar 25, the value is 9.31. This value is within the healthy range. It has decreased from 9.98 (Mar 24) to 9.31, marking a decrease of 0.67.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.12. This value is within the healthy range. It has decreased from 2.20 (Mar 24) to 2.12, marking a decrease of 0.08.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 2.06. This value is within the healthy range. It has decreased from 2.14 (Mar 24) to 2.06, marking a decrease of 0.08.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.12. This value is within the healthy range. It has decreased from 2.20 (Mar 24) to 2.12, marking a decrease of 0.08.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.05, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aurobindo Pharma Ltd:
- Net Profit Margin: 11.08%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 15.82% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.67% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.69
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.13
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 20.4 (Industry average Stock P/E: 52.39)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.24
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.08%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No.2, Maitri Vihar, Hyderabad Telangana 500038 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. M Ramasubramanian Kumar | Non Exe.Chairman&Ind.Director |
| Mr. K Nithyananda Reddy | Vice Chairman & Mng.Director |
| Mr. M Madan Mohan Reddy | Whole Time Director |
| Mr. P V Ramprasad Reddy | Non Executive Director |
| Dr. Satakarni Makkapati | Non Executive Director |
| Mr. P Sarath Chandra Reddy | Non Executive Director |
| Mr. Girish P Vanvari | Independent Director |
| Mr. Santanu Mukherjee | Independent Director |
| Dr. Deepali Pant Joshi | Independent Director |
FAQ
What is the intrinsic value of Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd's intrinsic value (as of 29 December 2025) is 1095.95 which is 8.90% lower the current market price of 1,203.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 69,891 Cr. market cap, FY2025-2026 high/low of 1,365/994, reserves of ₹34,983 Cr, and liabilities of 52,546 Cr.
What is the Market Cap of Aurobindo Pharma Ltd?
The Market Cap of Aurobindo Pharma Ltd is 69,891 Cr..
What is the current Stock Price of Aurobindo Pharma Ltd as on 29 December 2025?
The current stock price of Aurobindo Pharma Ltd as on 29 December 2025 is 1,203.
What is the High / Low of Aurobindo Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aurobindo Pharma Ltd stocks is 1,365/994.
What is the Stock P/E of Aurobindo Pharma Ltd?
The Stock P/E of Aurobindo Pharma Ltd is 20.4.
What is the Book Value of Aurobindo Pharma Ltd?
The Book Value of Aurobindo Pharma Ltd is 603.
What is the Dividend Yield of Aurobindo Pharma Ltd?
The Dividend Yield of Aurobindo Pharma Ltd is 0.33 %.
What is the ROCE of Aurobindo Pharma Ltd?
The ROCE of Aurobindo Pharma Ltd is 14.2 %.
What is the ROE of Aurobindo Pharma Ltd?
The ROE of Aurobindo Pharma Ltd is 11.1 %.
What is the Face Value of Aurobindo Pharma Ltd?
The Face Value of Aurobindo Pharma Ltd is 1.00.